

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/002,361	11/23/2001	Mark S. Pelak	MSP-2	5889
7590 08/17/2004			EXAMINER	
Allen D. Brufsky, PA			BUMGARNER, MELBA N	
FERRELL SCHULTZ CARTER ZUMPANO & FERTEL 201 SOUTH BISCAYNE BOULEVARD			ART UNIT	PAPER NUMBER
34TH FLOOR, MIAMI CENTER			3732	
MIAMI, FL 3	3131-4325		DATE MAILED: 08/17/2004	1

Please find below and/or attached an Office communication concerning this application or proceeding.

## Advisory Action Application No. Applicant(s) 10/002,361 PELAK, MARK S. Examiner Art Unit Melba Bumgarner 3732

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 29 July 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

Examination (RCE) in compliance with 37 CFR 1.114.	), or (3) a timely filed request for continued
PERIOD FOR REPLY [check either	er a) or b)]
<ul> <li>a)</li></ul>	) the date set forth in the final rejection, whichever is later. In
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the pe fee have been filed is the date for purposes of determining the period of extension and the c fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statuto (2) as set forth in (b) above, if checked. Any reply received by the Office later than three motimely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).	corresponding amount of the fee. The appropriate extension by period for reply originally set in the final Office action; or
1. A Notice of Appeal was filed on Appellant's Brief must be file 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avo	
2. The proposed amendment(s) will not be entered because:	
(a) 🛛 they raise new issues that would require further consideration a	and/or search (see NOTE below);
<ul><li>(b)  they raise the issue of new matter (see Note below);</li></ul>	
<ul> <li>(c)  they are not deemed to place the application in better form for a issues for appeal; and/or</li> </ul>	appeal by materially reducing or simplifying the
(d) They present additional claims without canceling a corresponding	ng number of finally rejected claims.
NOTE: See Continuation Sheet.	
3. Applicant's reply has overcome the following rejection(s):	
4. Newly proposed or amended claim(s) would be allowable if su canceling the non-allowable claim(s).	ubmitted in a separate, timely filed amendment
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration is application in condition for allowance because:	has been considered but does NOT place the
6. The affidavit or exhibit will NOT be considered because it is not direct raised by the Examiner in the final rejection.	cted SOLELY to issues which were newly
7. ☑ For purposes of Appeal, the proposed amendment(s) a) ☑ will not be explanation of how the new or amended claims would be rejected is	
The status of the claim(s) is (or will be) as follows:	•
Claim(s) allowed:	
Claim(s) objected to:	,
Claim(s) rejected: <u>1-8 and 10-16</u> .	
Claim(s) withdrawn from consideration:	
8. The drawing correction filed on is a) approved or b) dis	sapproved by the Examiner.
9. Note the attached Information Disclosure Statement(s)( PTO-1449)	Paper No(s)
10. Other:	·
	mella Rumana
	Melba Bumgarner Melba Bumgarner
	Melba bumgarner

U.S. Patent and Trademark Office PTOL-303 (Rev. 11-03) Continuation of 2. NOTE: The proposed amendment raises new issue that would require further consideration and/or search of the limitation of "extended" tapered surface of the implant abutment added to the independent claims.